Drugs / EWSR1 immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07695311 | Oct 2026 → Oct 2029 expected | Ewing sarcoma, desmoplastic small round cell tumor | Rabi Hanna | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EWSR1 immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07695311 ↗ |
| Modality | Messenger RNA (mRNA) | “a lipid nanoparticle coated with EWSR1 mRNA” NCT07695311 ↗ |
| Route | Intramuscular | “through an intramuscular injection” NCT07695311 ↗ |
| Target | EWSR1 | “designed to target a specific genetic change (EWSR1 fusion gene)” NCT07695311 ↗ |